Latest Breaking News On - Etienne montagut - Page 1 : comparemela.com

Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyLos angelesEtienne montagutMark kinarneyUniversity of californiaSecurities exchangeEuropean association of nuclear medicineExchange commissionCorporate communicationsLantheus holdings incDepartment of radiation oncologyNuclear medicineAnnual meetingChief business officerRated oral presentation

Ratio Therapeutics announces first patient dosed in FAP-targeted radiopharmaceutical study

Boston-based pharma company Ratio Therapeutics has initiated dosing in a phase 1 study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical, RTX-1363S, for PET imaging in adult healthy volunteers.

Scott holbrookJohn babichEtienne montagutRatio therapeuticsBio developmentsClinical trial

Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe

Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesFrance generalEtienne montagutRoss bethellPierre curieBenoit woessmerMedicinal productsHuman useEuropean medicines agencyEuropean phaseChief business officerDie experten

Credit Suisse AG Boosts Stock Holdings in Lantheus Holdings, Inc (NASDAQ:LNTH)

Credit Suisse AG raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 1.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,765 shares of the medical equipment provider’s stock after purchasing an additional 841 shares during the period. […]

Andrea sabensEtienne montagutWolverine asset managementClearstead advisorsLantheus holdings incNational bankSecurities exchange commissionAlphamark advisorsCoppell advisory solutions corpLantheus holdingsFree reportAsset managementMark advisorsAdvisory solutionsGet free reportLantheus daily

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers

Etienne montagutJohn babichScott holbrookRatio therapeutics incRatio therapeuticsChief scientificLantheu chief businessChief strategy officerGeneral manager